Puberty and its disorders in the male

Pediatric Endocrinology: Fourth Edition

Volumn , Issue , 2014, Pages

  Palmert, Mark R ^a,b   Dunkel, Leo ^c   Witchel, Selma Feldman ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902423212     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4858-7.00026-3     Document Type: Chapter

References (297)

1. Patton G.C, Viner R. Pubertal transitions in health. Lancet 2007, 369:1130-1139.
2. Wierman M.E, Kiseljak-Vassiliades K., Tobet S Gonadotropin-releasing hormone (GnRH) neuron migration. initiation, maintenance and cessation as critical steps to ensure normal reproductive function. Front Neuroendocrinol 2011, 32:43-52.
3. Miraoui H., Dwyer A.A, Sykiotis G.P, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet 2013, 92(2):725-743.
4. El Majdoubi M., Sahu A., Ramaswamy S., Plant T.M Neuropeptide Y. a hypothalamic brake restraining the onset of puberty in primates. Proc Natl Acad Sci USA 2000, 97:6179-6184.
5. O'Shaughnessy P.J, Baker P.J, Monteiro A., et al. Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester. J Clin Endocrinol Metab 2007, 92:4792-4801.
6. Wilhelm D., Palmer S., Koopman P. Sex determination and gonadal development in mammals. Physiol Rev 2007, 87:81.
7. Valeri C., Schteingart H.F, Rey R.A The prepubertal testis. biomarkers and functions. Curr Opin Endocrinol Diabetes Obes 2013, 20:224-233.
8. Bay K., Main K.M, Toppari J., Skakkebæk N.E Testicular descent. INSL3, testosterone, genes and the intrauterine milieu. Nat Rev Urol 2011, 8:187-196.
9. Kuiri-Hanninen T., Seuri R., Tyrvainen E., et al. Increased activity of the hypothalamic-pituitary-testicular axis in infancy results in increased androgen action in premature boys. J Clin Endocrinol Metab 2011, 96:98-105.
10. Boukari K., Meduri G., Brailly-Tabard S., et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. J Clin Endocrinol Metab 2009, 94:1818-1825.
11. Rey R.A, Grinspon R.P, Gottlieb S., et al. Male hypogonadism. an extended classification based on a developmental, endocrine physiology-based approach. Andrology 2013, 1:3-16.
12. Josso N., Picard J.Y, Rey R., di-Clemente N Testicular anti-Müllerian hormone. history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006, 3:347-358.
13. Jensen T.K, Andersson A.M, Hjollund N.H, et al. Inhibin B as a serum marker of spermatogenesis. correlation to differences in sperm concentration and follicle-stimulating hormone levelsa study of 349 Danish men. J Clin Endocrinol Metab 1997, 82:4059-4063.
14. Nielsen C.T, Skakkebaek N.E, Richardson D.W, et al. Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. J Clin Endocrinol Metab 1986, 62:532-535.
15. Dunkel L., Perheentupa J., Apter D. Kinetics of the steroidogenic response to single versus repeated doses of human chorionic gonadotropin in boys in prepuberty and early puberty. Pediatr Res 1985, 19:1-4.
16. Dunkel L., Alfthan H., Stenman U.H, Perheentupa J. Gonadal control of pulsatile secretion of luteinizing hormone and follicle-stimulating hormone in prepubertal boys evaluated by ultrasensitive time-resolved immunofluorometric assays. J Clin Endocrinol Metab 1990, 70:107-114.
17. Dunkel L., Alfthan H., Stenman U.H, et al. Pulsatile secretion of LH and FSH in prepubertal and early pubertal boys revealed by ultrasensitive time-resolved immunofluorometric assays. Pediatr Res 1990, 27:215-219.
18. Apter D., Butzow T.L, Laughlin G.A, Yen S.S Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls. pulsatile and diurnal patterns of circulating gonadotropins. J Clin Endocrinol Metab 1993, 76:940-949.
19. Wu F.C, Butler G.E, Kelnar C.J, et al. Ontogeny of pulsatile gonadotropin releasing hormone secretion from midchildhood, through puberty, to adulthood in the human male. a study using deconvolution analysis and an ultrasensitive immunofluorometric assay. J Clin Endocrinol Metab 1996, 81:1798-1805.
20. Dunkel L., Alfthan H., Stenman U.H, et al. Developmental changes in 24-hour profiles of luteinizing hormone and follicle-stimulating hormone from prepuberty to midstages of puberty in boys. J Clin Endocrinol Metab 1992, 74:890-897.
21. Albertsson-Wikland K., Rosberg S., Lannering B., et al. Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels. a semilongitudinal study throughout puberty in healthy boys. J Clin Endocrinol Metab 1997, 82:541-549.
22. de Roux N., Genin E., Carel J.C, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003, 100:10972-10976.
23. Seminara S.B, Messager S., Chatzidaki E.E, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003, 349:1614-1627.
24. Teles M.G, Bianco S.D, Brito V.N, et al. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008, 358:709-715.
25. Seminara S.B Kisspeptin in reproduction. Semin Reprod Med 2007, 25:337-343.
26. Roth C.L, Mastronardi C., Lomniczi A., et al. Expression of a tumor-related gene network increases in the mammalian hypothalamus at the time of female puberty. Endocrinology 2007, 148:5147-5161.
27. Topaloglu A.K, Reimann F., Guclu M., et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009, 41:354-358.
28. Eghlidi D.H, Haley G.E, Noriega N.C, et al. Influence of age and 17beta-estradiol on kisspeptin, neurokinin B, and prodynorphin gene expression in the arcuate-median eminence of female rhesus macaques. Endocrinology 2010, 151:3783-3794.
29. Topaloglu A.K, Semple R.K Neurokinin B signalling in the human reproductive axis. Mol Cell Endocrinol 2011, 346:57-64.
30. Navarro V.M, Gottsch M.L, Wu M., et al. Regulation of NKB pathways and their roles in the control of Kiss1 neurons in the arcuate nucleus of the male mouse. Endocrinology 2011, 152:4265-4275.
31. Prevot V., Rio C., Cho G.J, et al. Normal female sexual development requires neuregulin-erbB receptor signaling in hypothalamic astrocytes. J Neurosci 2003, 23:230-239.
32. Gottsch M.L, Clifton D.K, Steiner R.A Galanin-like peptide as a link in the integration of metabolism and reproduction. Trends Endocrinol Metab 2004, 15:215-221.
33. Gottsch M.L, Cunningham M.J, Smith J.T, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology 2004, 145:4073-4077.
34. Plant T.M, Barker-Gibb M.L Neurobiological mechanisms of puberty in higher primates. Hum Reprod Update 2004, 10:67-77.
35. Terasawa E., Fernandez D.L Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev 2001, 22:111-151.
36. Ojeda S.R, Prevot V., Heger S., et al. Glia-to-neuron signaling and the neuroendocrine control of female puberty. Ann Med 2003, 35:244-255.
37. Mitsushima D., Hei D.L, Terasawa E. gamma-Aminobutyric acid is an inhibitory neurotransmitter restricting the release of luteinizing hormone-releasing hormone before the onset of puberty. Proc Natl Acad Sci USA 1994, 91:395-399.
38. Rivera C., Voipio J., Payne J.A, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999, 397:251-255.
39. Marshall W.A, Tanner J.M Variations in pattern of pubertal changes in girls. Archives of disease in childhood 1969, 44:291-303.
40. Marshall W.A, Tanner J.M Variations in the pattern of pubertal changes in boys. Archives of disease in childhood 1970, 45:13-23.
41. Largo R.H, Prader A. Pubertal development in Swiss boys. Helv Paediatr Acta 1983, 38:211-228.
42. Roche A.F, Wellens R., Attie K.M, Siervogel R.M The timing of sexual maturation in a group of US white youths. J Pediatr Endocrinol Metab 1995, 8:11-18.
43. Juul A., Teilmann G., Scheike T., et al. Pubertal development in Danish children. comparison of recent European and US data. Int J Androl 2006, 29:247-255. 86-90; discussion.
44. Harlan W.R, Grillo G.P, Cornoni-Huntley J., Leaverton P.E Secondary sex characteristics of boys 12 to 17 years of age. the U.S. Health Examination Survey. J Pediatr 1979, 95:293-297.
45. Harlan W.R, Harlan E.A, Grillo G.P Secondary sex characteristics of girls 12 to 17 years of age. the U.S. Health Examination Survey. J Pediatr 1980, 96:1074-1078.
46. Palmert M.R, Hayden D.L, Mansfield M.J, et al. The longitudinal study of adrenal maturation during gonadal suppression. evidence that adrenarche is a gradual process. J Clin Endocrinol Metab 2001, 86:4536-4542.
47. Sklar C.A, Kaplan S.L, Grumbach M.M Evidence for dissociation between adrenarche and gonadarche. studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. J Clin Endocrinol Metab 1980, 51:548-556.
48. Wierman M.E, Beardsworth D.E, Crawford J.D, et al. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche. J Clin Invest 1986, 77:121-126.
49. Remer T., Manz F. Role of nutritional status in the regulation of adrenarche. J Clin Endocrinol Metab 1999, 84:3936-3944.
50. Ong K.K, Potau N., Petry C.J, et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004, 89:2647-2651.
51. Topor L.S, Asai M., Dunn J., Majzoub J.A Cortisol stimulates secretion of dehydroepiandrosterone in human adrenocortical cells through inhibition of 3betaHSD2. J Clin Endocrinol Metab 2011, 96:E31-E39.
52. Parent A.S, Teilmann G., Juul A., et al. The timing of normal puberty and the age limits of sexual precocity. variations around the world, secular trends, and changes after migration. Endocr Rev 2003, 24:668-693.
53. Gajdos Z.K, Hirschhorn J.N, Palmert M.R What controls the timing of puberty? An update on progress from genetic investigation. Curr Opin Endocrinol Diabetes Obes 2009, 16:16-24.
54. Fischbein S. Onset of puberty in MX and DZ twins. Acta Genet Med Gemellol (Roma) 1977, 26:151-158.
55. Sklad M. The rate of growth and maturing of twins. Acta Genet Med Gemellol (Roma) 1977, 26:221-237.
56. Kaprio J., Rimpela A., Winter T., et al. Common genetic influences on BMI and age at menarche. Hum Biol 1995, 67:739-753.
57. van den Berg S.M, Boomsma D.I The familial clustering of age at menarche in extended twin families. Behav Genet 2007, 37:661-667.
58. Hodges C.A, Palmert M.R Genetic regulation of the variation in pubertal timing. When puberty is precocious: scientific and clinical aspects 2007, 83-102. Humana Press, Totowa, NJ. O.H. Pescovitz, E.C. Walvoord (Eds.).
59. Palmert M.R, Hirschhorn J.N Genetic approaches to stature, pubertal timing, and other complex traits. Mol Genet Metab 2003, 80:1-10.
60. Towne B., Czerwinski S.A, Demerath E.W, et al. Heritability of age at menarche in girls from the Fels Longitudinal Study. Am J Phys Anthropol 2005, 128:210-219.
61. Morris D.H, Jones M.E, Schoemaker M.J, et al. Familial concordance for age at menarche. analyses from the Breakthrough Generations Study. Paediatr Perinat Epidemiol 2011, 25:306-311.
62. Bianco S.D, Kaiser U.B The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009, 5:569-576.
63. Bhangoo A., Jacobson-Dickman E. The genetics of idiopathic hypogonadotropic hypogonadism. unraveling the biology of human sexual development. Pediatr Endocrinol Rev 2009, 6:395-404.
64. Herbison A.E Genetics of puberty. Horm Res 2007, 68(Suppl. 5):75-79.
65. Kalantaridou S.N, Chrousos G.P Clinical review 148. monogenic disorders of puberty. J Clin Endocrinol Metab 2002, 87:2481-2494.
66. Silveira L.F, MacColl G.S, Bouloux P.M Hypogonadotropic hypogonadism. Semin Reprod Med 2002, 20:327-338.
67. Martin C., Balasubramanian R., Dwyer A.A, et al. The role of the prokineticin 2 pathway in human reproduction. evidence from the study of human and murine gene mutations. Endocr Rev 2011, 32:225-246.
68. Sykiotis G.P, Plummer L., Hughes V.A, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA 2010, 107:15140-15144.
69. Abreu A.P, Dauber A., Macedo D.B, et al. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med 2013, 368:2467-2475.
70. Shahab M., Mastronardi C., Seminara S.B, et al. Increased hypothalamic GPR54 signaling. a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci USA 2005, 102:2129-2134.
71. Bedecarrats G.Y, Kaiser U.B Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused L beta T2 cells. role of GnRH receptor concentration. Endocrinology 2003, 144:1802-1811.
72. Bedecarrats G.Y, Linher K.D, Janovick J.A, et al. Four naturally occurring mutations in the human GnRH receptor affect ligand binding and receptor function. Mol Cell Endocrinol 2003, 205:51-64.
73. Bedecarrats G.Y, Linher K.D, Kaiser U.B Two common naturally occurring mutations in the human gonadotropin-releasing hormone (GnRH) receptor have differential effects on gonadotropin gene expression and on GnRH-mediated signal transduction. J Clin Endocrinol Metab 2003, 88:834-843.
74. Karges B., de Roux N. Molecular genetics of isolated hypogonadotropic hypogonadism and Kallmann syndrome. Endocr Dev 2005, 8:67-80.
75. Bhagavath B., Ozata M., Ozdemir I.C, et al. The prevalence of gonadotropin-releasing hormone receptor mutations in a large cohort of patients with hypogonadotropic hypogonadism. Fertil Steril 2005, 84:951-957.
76. Beranova M., Oliveira L.M, Bedecarrats G.Y, et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2001, 86:1580-1588.
77. Chan Y.M, de Guillebon A., Lang-Muritano M., et al. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2009, 106:11703-11708.
78. Bouligand J., Ghervan C., Tello J.A, et al. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 2009, 360:2742-2748.
79. Lin L., Conway G.S, Hill N.R, et al. A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J Clin Endocrinol Metab 2006, 91:5117-5121.
80. Sedlmeyer I.L, Pearce C.L, Trueman J.A, et al. Determination of sequence variation and haplotype structure for the gonadotropin-releasing hormone (GnRH) and GnRH receptor genes. investigation of role in pubertal timing. J Clin Endocrinol Metab 2005, 90:1091-1099.
81. Gajdos Z.K, Butler J.L, Henderson K.D, et al. Association studies of common variants in 10 hypogonadotropic hypogonadism genes with age at menarche. J Clin Endocrinol Metab 2008, 93:4290-4298.
82. Franco B., Guioli S., Pragliola A., et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991, 353:529-536.
83. Legouis R., Hardelin J.P, Levilliers J., et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991, 67:423-435.
84. Dode C., Levilliers J., Dupont J.M, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003, 33:463-465.
85. Dode C., Teixeira L., Levilliers J., et al. Kallmann syndrome. mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006, 2:e175.
86. Kramer P.R, Wray S. Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neurons. Genes Dev 2000, 14:1824-1834.
87. Miura K., Acierno J.S, Seminara S.B Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). J Hum Genet 2004, 49:265-268.
88. Pitteloud N., Quinton R., Pearce S., et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007, 117:457-463.
89. Xu N., Kim H.G, Bhagavath B., et al. Nasal embryonic LHRH factor (NELF) mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2011, 95:1613-1620. e1-e7.
90. Cole L.W, Sidis Y., Zhang C., et al. Mutations in prokineticin 2 (PROK2) and PROK2 receptor (PROKR2) in human gonadotrophin-releasing hormone deficiency. molecular genetics and clinical spectrum. J Clin Endocrinol Metab 2008, 93:3551-3559.
91. Falardeau J., Chung W.C, Beenken A., et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008, 118:2822-2831.
92. Kim H.G, Kurth I., Lan F., et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008, 83:511-519.
93. Jongmans M.C, van Ravenswaaij-Arts C.M, Pitteloud N., et al. CHD7 mutations in patients initially diagnosed with Kallmann syndrome-the clinical overlap with CHARGE syndrome. Clin Genet 2009, 75:65-71.
94. Raivio T., Avbelj M., McCabe M.J, et al. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J Clin Endocrinol Metab 2012, 97:E694-E699.
95. Reynaud R., Jayakody S.A, Monnier C., et al. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab 2012, 97:E1068-E1073.
96. Pitteloud N., Acierno J.S, Meysing A.U, et al. Reversible Kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene. J Clin Endocrinol Metab 2005, 90:1317-1322.
97. Pitteloud N., Meysing A., Quinton R., et al. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol 2006, 254-255:60-69.
98. Raivio T., Falardeau J., Dwyer A., et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007, 357:863-873.
99. Banerjee I., Trueman J.A, Hall C.M, et al. Phenotypic variation in constitutional delay of growth and puberty. relationship to specific leptin and leptin receptor gene polymorphisms. Eur J Endocrinol 2006, 155:121-126.
100. Jackson R.S, Creemers J.J, Ohagi S., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:303-306.
101. Gajdos Z.K, Henderson K.D, Hirschhorn J.N, Palmert M.R Genetic determinants of pubertal timing in the general population. Mol Cell Endocrinol 2010, 324:21-29.
102. Vaaralahti K., Wehkalampi K., Tommiska J., et al. The role of gene defects underlying isolated hypogonadotropic hypogonadism in patients with constitutional delay of growth and puberty. Fertil Steril 2011, 95:2756-2758.
103. He C., Kraft P., Chen C., et al. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet 2009, 41:724-728.
104. Elks C.E, Perry J.R, Sulem P., et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet 2010, 42:1077-1085.
105. Perry J.R, Stolk L., Franceschini N., et al. Meta-analysis of genome-wide association data identifies two loci influencing age at menarche. Nat Genet 2009, 41:648-650.
106. Sulem P., Gudbjartsson D.F, Rafnar T., et al. Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet 2009, 41:734-738.
107. Ong K.K, Elks C.E, Li S., et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat Genet 2009, 41:729-733.
108. Hirschhorn J.N Genomewide association studies-illuminating biologic pathways. N Engl J Med 2009, 360:1699-1701.
109. Caronia L.M, Martin C., Welt C.K, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 2011, 364:215-225.
110. Biro F.M, Khoury P., Morrison J.A Influence of obesity on timing of puberty. Int J Androl 2006, 29:272-277. discussion 86-90.
111. Ellis B.J, Essex M.J Family environments, adrenarche, and sexual maturation. a longitudinal test of a life history model. Child Dev 2007, 78:1799-1817.
112. Euling S.Y, Herman-Giddens M.E, Lee P.A, et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends. panel findings. Pediatrics 2008, 121(Suppl. 3):S172-S191.
113. Karpati A.M, Rubin C.H, Kieszak S.M, et al. Stature and pubertal stage assessment in American boys. the 1988-1994 Third National Health and Nutrition Examination. J Adolesc Health 2002, 30:205-212.
114. Sun S.S, Schubert C.M, Chumlea W.C, et al. National estimates of the timing of sexual maturation and racial differences among US children. Pediatrics 2002, 110,:911-919.
115. Sun S.S, Schubert C.M, Liang R., et al. Is sexual maturity occurring earlier among U.S. children. J Adolesc Health 2005, 37:345-355.
116. Herman-Giddens M.E, Wang L., Koch G. Secondary sexual characteristics in boys. estimates from the national health and nutrition examination survey III, 1988-1994. Arch Pediatr Adolesc Med 2001, 155:1022-1028.
117. Biro F.M, Lucky A.W, Huster G.A, Morrison J.A Pubertal staging in boys. J Pediatr 1995, 127:100-102.
118. Lee P.A, Guo S.S, Kulin H.E Age of puberty. data from the United States of America. Apmis 2001, 109:81-88.
119. Sorensen K., Nielsen J., Busch P., et al. Measurement of testicular volume with Prader's orchidometer in 1,389 boys 5-151/2 years old. Ugeskrift for laeger 1979, 141:915-918.
120. Mul D., Fredriks A.M, van Buuren S., et al. Pubertal development in The Netherlands 1965-1997. Pediatric Res 2001, 50:479-486.
121. Sorensen K., Aksglaede L., Petersen J.H, Juul A. Recent changes in pubertal timing in healthy Danish boys. associations with body mass index. J Clin Endocrinol Metab 2010, 95:263-270.
122. Kaplowitz P.B Link between body fat and the timing of puberty. Pediatrics 2008, 121(Suppl. 3):S208-S217.
123. Herman-Giddens M.E, Slora E.J, Wasserman R.C, et al. Secondary sexual characteristics and menses in young girls seen in office practice. a study from the Pediatric Research in Office Settings network. Pediatrics 1997, 99:505-512.
124. Foster T.A, Voors A.W, Webber L.S, et al. Anthropometric and maturation measurements of children, ages 5 to 14 years, in a biracial community-the Bogalusa Heart Study. Am J Clin Nutr 1977, 30:582-591.
125. Nathan B.M, Sedlmeyer I.L, Palmert M.R Impact of body mass index on growth in boys with delayed puberty. J Pediatr Endocrinol Metab 2006, 19:971-977.
126. Kaplowitz P. Delayed puberty in obese boys. comparison with constitutional delayed puberty and response to testosterone therapy. J Pediatr 1998, 133:745-749.
127. Sandhu J., Ben-Shlomo Y., Cole T.J, et al. The impact of childhood body mass index on timing of puberty, adult stature and obesity. a follow-up study based on adolescent anthropometry recorded at Christ's Hospital (1936-1964). Int J Obes (Lond) 2006, 30:14-22.
128. He Q., Karlberg J. BMI in childhood and its association with height gain, timing of puberty, and final height. Pediatr Res 2001, 49:244-251.
129. Juul A., Magnusdottir S., Scheike T., et al. Age at voice break in Danish boys. effects of pre-pubertal body mass index and secular trend. Int J Androl 2007, 30:537-542.
130. Boyne M.S, Osmond C., Fraser R.A, et al. Developmental origins of cardiovascular risk in Jamaican children. the Vulnerable Windows Cohort study. Br J Nutr 2010, 104:1026-1033.
131. Boyne M.S, Thame M., Osmond C., et al. Growth, body composition, and the onset of puberty. longitudinal observations in Afro-Caribbean children. J Clin Endocrinol Metab 2010, 95:3194-3200.
132. Heger S., Korner A., Meigen C., et al. Impact of weight status on the onset and parameters of puberty. analysis of three representative cohorts from central Europe. J Pediatr Endocrinol Metab 2008, 21:865-877.
133. Meigen C., Keller A., Gausche R., et al. Impact of weight status on the onset and parameters of puberty. analysis of three representative cohorts from central Europe. Metabolism 2008, 57:934-939.
134. Mouritsen A., Aksglaede L., Sorensen K., et al. Hypothesis. exposure to endocrine-disrupting chemicals may interfere with timing of puberty. Int J Androl 2010, 33:346-359.
135. Toppari J., Juul A. Trends in puberty timing in humans and environmental modifiers. Mol Cell Endocrinol 2010, 324:39-44.
136. Massart F., Saggese G. Oestrogenic mycotoxin exposures and precocious pubertal development. Int J Androl 2010, 33:369-376.
137. Frederiksen H., Sorensen K., Mouritsen A., et al. High urinary phthalate concentration associated with delayed pubarche in girls. Int J Androl 2012, 35:216-226.
138. Toppari J., Virtanen H.E, Main K.M, Skakkebaek N.E Cryptorchidism and hypospadias as a sign of testicular dysgenesis syndrome (TDS). environmental connection. Birth Defects Res A Clin Mol Teratol 2010, 88:910-919.
139. Skakkebaek N.E, Toppari J., Soder O., et al. The exposure of fetuses and children to endocrine disrupting chemicals. a European Society for Paediatric Endocrinology (ESPE) and Pediatric Endocrine Society (PES) call to action statement. J Clin Endocrinol Metab 2011, 96:3056-3058.
140. Sharpe R.M Pediatrics. endocrine disruption and human health effects-a call to action. Nat Rev Endocrinol 2011, 7:633-634.
141. Nathan B.M, Palmert M.R Regulation and disorders of pubertal timing. Endocrinol Metab Clin North Am 2005, 34:617-641. ix.
142. Carel J.C, Leger J. Clinical practice. precocious puberty. N Engl J Med 2008, 358:2366-2377.
143. Virdis R., Street M.E, Bandello M.A, et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab 2003, 16(Suppl. 2):289-292.
144. Kaulfers A.M, Backeljauw P.F, Reifschneider K., et al. Endocrine dysfunction following traumatic brain injury in children. J Pediatr 2010, 157:894-899.
145. Shenker A., Laue L., Kosugi S., et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993, 365:652-654.
146. Schedewie H.K, Reiter E.O, Beitins I.Z, et al. Testicular Leydig cell hyperplasia as a cause of familial sexual precocity. J Clin Endocrinol Metab 1981, 52:271-278.
147. Latronico A.C, Segaloff D.L Naturally occurring mutations of the luteinizing-hormone receptor. lessons learned about reproductive physiology and G protein-coupled receptors. Am J Hum Genet 1999, 65:949-958.
148. Shenker A., Weinstein L.S, Moran A., et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993, 123:509-518.
149. Mamkin I., Philibert P., Anhalt H., et al. Unusual phenotypical variations in a boy with McCune-Albright syndrome. Horm Res Paediatr 2010, 73:215-222.
150. Lala R., Matarazzo P., Andreo M., et al. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002, 15(Suppl. 3):913-920.
151. Van Wyk J.J, Grumbach M.M Syndrome of precocious menstruation and galactorrhoea in juvenile hypothyroidism. an example of hormonal overlap in pituitary feedback. J Pediatr 1960, 57:416-435.
152. Anasti J.N, Flack M.R, Froehlich J., et al. A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab 1995, 80:276-279.
153. Bruder J.M., Samuels M.H., Bremner W.J., et al. Hypothyroidism-induced macroorchidism. use of a gonadotropin-releasing hormone agonist to understand its mechanism and augment adult stature. J Clin Endocrinol Metab 1995, 80:11-16.
154. Durbin K.L., Diaz-Montes T., Loveless M.B. Van Wyk and Grumbach syndrome. an unusual case and review of the literature. J Pediatr Adolesc Gynecol 2011, 24:e93-e96.
155. Boot A.M., Lumbroso S., Verhoef-Post M., et al. Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene. J Clin Endocrinol Metab 2011, 96:E1197-E1205.
156. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab 2004, 89:3644-3650.
157. Palmert M.R., Malin H.V., Boepple P.A. Unsustained or slowly progressive puberty in young girls. initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999, 84:415-423.
158. Bordini B., Littlejohn E., Rosenfield R.L. LH Dynamics in overweight girls with premature adrenarche and slowly progressive sexual precocity. Int J Pediatr Endocrinol http://dx.doi:10.1155/2010/724696.
159. Klein K.O. Precocious puberty. who has it? Who should be treated. J Clin Endocrinol Metab 1999, 84:411-414.
160. Carel J.C., Lahlou N., Roger M, Chaussain J.L. Precocious puberty and statural growth. Hum Reprod Update 2004, 10:135-147.
161. Tremblay L., Frigon J.Y. Precocious puberty in adolescent girls. a biomarker of later psychosocial adjustment problems. Child Psychiatry Hum Dev 2005, 36:73-94.
162. Michaud P.A., Suris J.C., Deppen A. Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. Mol Cell Endocrinol 2006, 254-255:172-178.
163. Carel J.C., Eugster E.A., Rogol A., et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009, 123:e752-e762.
164. Henley D.V., Lipson N., Korach K.S., Bloch C.A. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007, 356:479-485.
165. Neely E.K., Hintz R.L., Wilson D.M., et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995, 127:40-46.
166. Neely E.K., Wilson D.M., Lee P.A., et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995, 127:47-52.
167. Pescovitz O.H., Hench K.D., Barnes K.M., et al. Premature thelarche and central precocious puberty. the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1988, 67:474-479.
168. De Sanctis V., Corrias A., Rizzo V., et al. Etiology of central precocious puberty in males. the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000, 13(Suppl. 1):687-693.
169. Cisternino M., Arrigo T., Pasquino A.M., et al. Etiology and age incidence of precocious puberty in girls. a multicentric study. J Pediatr Endocrinol Metab 2000, 13(Suppl. 1):695-701.
170. Bar A., Linder B., Sobel E.H., et al. Bayley-Pinneau method of height prediction in girls with central precocious puberty. correlation with adult height. J Pediatr 1995, 126:955-958.
171. Mul D., Bertelloni S., Carel J.C., et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. final height results. Horm Res 2002, 58:1-7.
172. Bertelloni S., Mul D. Treatment of central precocious puberty by GnRH analogs. long-term outcome in men. Asian J Androl 2008, 10:525-534.
173. Neely E.K., Lee P.A., Bloch C.A., et al. Leuprolide acetate 1-month depot for central precocious puberty. hormonal suppression and recovery. Int J Pediatr Endocrinol 2010, 2010:398639.
174. Lee P.A., Neely E.K., Fuqua J., et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011, 2011:2017.
175. Trueman J.A., Tillmann V., Cusick C.F., et al. Suppression of puberty with long-acting goserelin (Zoladex-LA). effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002, 57:223-230.
176. Lee P.A., Klein K., Mauras N., et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012, 97:1572-1580.
177. Eugster E.A., Clarke W., Kletter G.B., et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty. a multicenter trial. J Clin Endocrinol Metab 2007, 92:1697-1704.
178. Hirsch H.J., Gillis D., Strich D., et al. The histrelin implant. a novel treatment for central precocious puberty. Pediatrics 2005, 116:e798-802.
179. Rahhal S., Clarke W.L., Kletter G.B., et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol http://dx.doi:10.1155/2009/812517.
180. Almeida M.Q., Brito V.N., Lins T.S., et al. Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clin Endocrinol (Oxf) 2008, 69:93-98.
181. Babovic Vuksanovic D., Donaldson M.D., Gibson N.A., Wallace A.M. Hazards of ketoconazole therapy in testotoxicosis. Acta Paediatr 1994, 83:994-997.
182. Holland F.J., Fishman L., Bailey J.D., Fazekas A.T. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985, 312:1023-1028.
183. Rajfer J., Sikka S.C., Rivera F., Handelsman D.J. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. J Clin Endocrinol Metab 1986, 63:1193-1198.
184. Soriano-Guillen L., Lahlou N., Chauvet G., et al. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005, 90:147-151.
185. Laue L., Jones J., Barnes K.M., Cutler G.B. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993, 76:151-155.
186. Laue L., Kenigsberg D., Pescovitz O.H., et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989, 320:496-502.
187. Leschek E.W., Jones J., Barnes K.M., et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999, 84:175-178.
188. Merke D.P., Keil M.F., Jones J.V., et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000, 85:1114-1120.
189. Best T.R., Jenkins J.K., Murphy F.Y., et al. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med 1987, 82:676-680.
190. Eyssette-Guerreau S., Pinto G., Sultan A., et al. Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty. J Pediatr Endocrinol Metab 2008, 21:995-1002.
191. Hero M., Janne O.A., Nanto-Salonen K., et al. Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment. J Clin Endocrinol Metab 2005, 90:5141-5145.
192. Kreher N.C., Pescovitz O.H., Delameter P., et al. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006, 149:416-420.
193. Tessaris D., Matarazzo P., Mussa A., et al. Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome. Endocr J 2012, 59:111-117.
194. Hero M., Maury S., Luotoniemi E., et al. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010, 163:149-155.
195. Hero M., Toiviainen-Salo S., Wickman S., et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010, 25:1536-1543.
196. Palmert M.R., Dunkel L. Clinical practice. delayed puberty. N Engl J Med 2012, 366:443-453.
197. Wu T., Mendola P., Buck G.M. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls. the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002, 110:752-757.
198. Susman E.J., Houts R.M., Steinberg L., et al. Longitudinal development of secondary sexual characteristics in girls and boys between ages 91/2 and 151/2 years. Arch Pediatr Adolesc Med 2010, 164:166-173.
199. Aksglaede L., Sorensen K., Petersen J.H., et al. Recent decline in age at breast development. the Copenhagen Puberty Study. Pediatrics 2009, 123:e932-e939.
200. Albanese A., Stanhope R. Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995, 126:545-550.
201. Gilsanz V., Chalfant J., Kalkwarf H., et al. Age at onset of puberty predicts bone mass in young adulthood. J Pediatr 2011, 158:100-105. 5 e1-e2.
202. Sedlmeyer I.L., Palmert M.R. Delayed puberty. analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002, 87:1613-1620.
203. Han J.C., Balagopal P., Sweeten S., et al. Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J Clin Endocrinol Metab 2006, 91:2081-2086.
204. Wilson D.A., Hofman P.L., Miles H.L., et al. Enhanced insulin sensitivity in prepubertal children with constitutional delay of growth and development. J Pediatr 2010, 156:308-312.
205. Sedlmeyer I.L., Hirschhorn J.N., Palmert M.R. Pedigree analysis of constitutional delay of growth and maturation. determination of familial aggregation and inheritance patterns. J Clin Endocrinol Metab 2002, 87:5581-5586.
206. Wehkalampi K., Widen E., Laine T., et al. Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. J Clin Endocrinol Metab 2008, 93:723-728.
207. Tommiska J., Wehkalampi K., Vaaralahti K., et al. LIN28B in constitutional delay of growth and puberty. J Clin Endocrinol Metab 2010, 95:3063-3066.
208. Hay C., Wu F. Genetics and hypogonadotrophic hypogonadism. Curr Opin Obstet Gynecol 2002, 14:303-308.
209. McCabe M.J., Gaston-Massuet C., Tziaferi V., et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab 2011, 96:E1709-E1718.
210. Tornberg J., Sykiotis G.P., Keefe K., et al. Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism. Proc Natl Acad Sci USA 2011, 108:11524-11529.
211. Hanchate N.K., Giacobini P., Lhuillier P., et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet 2012, 8:e1002896.
212. Kim H.G., Ahn J.W., Kurth I., et al. WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2010, 87:465-479.
213. Gianetti E., Tusset C., Noel S.D., et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010, 95:2857-2867.
214. Laitinen E.M., Tommiska J., Sane T., et al. Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations. PLoS One 2012, 7:e39450.
215. Bédécarrats G.Y., Kaiser U.B. Mutations in the human gonadotropin-releasing hormone receptor. insights into receptor biology and function. Semin Reprod Med 2007, 25:368-378.
216. Peter M., Viemann M., Partsch C.J., Sippell W.G. Congenital adrenal hypoplasia. clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab 1998, 83:2666-2674.
217. Bojesen A., Juul S., Gravholt C.H. Prenatal and postnatal prevalence of Klinefelter syndrome. a national registry study. J Clin Endocrinol Metab 2003, 88:622-626.
218. Ottesen A.M., Aksglaede L., Garn I., et al. Increased number of sex chromosomes affects height in a nonlinear fashion. a study of 305 patients with sex chromosome aneuploidy. Am J Med Genet A 2010, 152A:1206-1212.
219. Sokol R.Z. It's not all about the testes. medical issues in Klinefelter patients. Fertil Steril 2012, 98:261-265.
220. Groth K.A., Skakkebæk A., Høst C., et al. Clinical review. Klinefelter syndrome-a clinical update. J Clin Endocrinol Metab 2013, 98:20-30.
221. Aksglaede L., Juul A. Testicular function and fertility in men with Klinefelter syndrome. a review. Eur J Endocrinol 2013, 168:R67-R76.
222. Oates R.D. The natural history of endocrine function and spermatogenesis in Klinefelter syndrome. what the data show. Fertil Steril 2012, 98:266-273.
223. Cox J.J., Willatt L., Homfray T., Woods C.G. A SOX9 duplication and familial 46,XX developmental testicular disorder. N Engl J Med 2011, 364:91-93.
224. Seeherunvong T., Perera E.M., Bao Y., et al. 46,XX sex reversal with partial duplication of chromosome arm 22q. Am J Med Genet A 2004, 127A:149-151.
225. Tomaselli S., Megiorni F., De Bernardo C., et al. Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation. Hum Mutat 2008, 29:220-226.
226. Cools M., Boter M., van Gurp R., et al. Impact of the Y-containing cell line on histological differentiation patterns in dysgenetic gonads. Clin Endocrinol (Oxf) 2007, 67:184-192.
227. Ankarberg-Lindgren C., Westphal O., Dahlgren J. Testicular size development and reproductive hormones in boys and adult males with Noonan syndrome. a longitudinal study. Eur J Endocrinol 2011, 165:137-144.
228. Vogels A., Moerman P., Frijns J.P., Bogaert G.A. Testicular histology in boys with Prader-Willi syndrome. fertile or infertile. J Urol 2008, 180(Suppl. 4):1800-1804.
229. Siemensma E.P., de Lind van Wijngaarden R.F., Otten B.J., et al. Testicular failure in boys with Prader-Willi syndrome. longitudinal studies of reproductive hormones. J Clin Endocrinol Metab 2012, 97:E452-E459.
230. El-Khairi R., Achermann J.C. Steroidogenic factor-1 and human disease. Semin Reprod Med 2012, 30:374-381.
231. Salameh W., Choucair M., Guo T.B., et al. Leydig cell hypoplasia due to inactivation of luteinizing hormone receptor by a novel homozygous nonsense truncation mutation in the seventh transmembrane domain. Mol Cell Endocrinol 2005, 229:57-64.
232. Baker B.Y., Lin L., Kim C.J., et al. Nonclassic congenital lipoid adrenal hyperplasia. a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006, 91:4781-4785.
233. Tee M.K., Abramsohn M., Loewenthal N., et al. Varied clinical presentations of seven patients with mutations in CYP11A1 encoding the cholesterol side-chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 2013, 98:713-720.
234. Gucev Z.S., Tee M.K., Chitayat D., et al. Distinguishing deficiencies in the steroidogenic acute regulatory protein and the cholesterol side chain cleavage enzyme causing neonatal adrenal failure. J Pediatr 2013, 162:819-822.
235. Belgini D.R., Mello M.P., Baptista M.T., et al. Six new cases confirm the clinical molecular profile of complete combined 17a-hydroxylase/ 17,20-lyase deficiency in Brazil. Arq Bras Endocrinol Metabol 2010, 54:711-716.
236. Idkowiak J., O'Riordan S., Reisch N., et al. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2011, 96:E453-E462.
237. Zachmann M., Völlmin J.A., Hamilton W., Prader A. Steroid 17,20-desmolase deficiency: a new cause of male pseudohermaphroditism. Clin Endocrinol (Oxf) 1972, 1:369-385.
238. Wilson J.D., Auchus R.J., Leihy M.W., et al. 5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate. Endocrinology 2003, 144:575-580.
239. Flück C.E., Meyer-Böni M., Pandey A.V., et al. Why boys will be boys. two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet 2011, 89:201-218.
240. Fenichel P., Paris F., Philibert P., et al. Molecular diagnosis of 5α-reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism. J Clin Endocrinol Metab 2013, 98:E1055-E1059.
241. Costa E.M., Domenice S., Sircili M.H., et al. DSD due to 5a-reductase 2 deficiency-from diagnosis to long term outcome. Semin Reprod Med 2012, 30:427-431.
242. Kalfa N., Philibert P., Werner R., et al. Minor hypospadias. the "tip of the iceberg" of the partial androgen insensitivity syndrome. PLOS One 2013, 8:e61824.
243. Gottlieb B., Beitel L.K., Nadarajah A., et al. The androgen receptor gene mutations database. 2012 update. Hum Mutat 2012, 33:887-894.
244. Farikullah J., Ehtisham S., Nappo S., et al. Persistent Müllerian duct syndrome. lessons learned from managing a series of eight patients over a 10-year period and review of literature regarding malignant risk from the Müllerian remnants. BJU Int 2012, 110(11 Pt. C):E1084-E1089.
245. Spires S.E., Woolums C.S., Pulito A.R., Spires S.M. Testicular regression syndrome. a clinical and pathologic study of 11 cases. Arch Pathol Lab Med 2000, 124:694-698.
246. Misra M., MacLaughlin D.T., Donahoe P.K., Lee M.M. Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab 2002, 87:3598-3602.
247. Brauner R., Neve M., Allali S., et al. Clinical, biological and genetic analysis of anorchia in 26 boys. PLoS One 2011, 6:e23292.
248. Kojima Y., Kohri K., Hayashi Y. Genetic pathway of external genitalia formation and molecular etiology of hypospadias. J Pediatr Urol 2010, 6:346-354.
249. Carmichael S.L., Shaw G.M., Lammer E.J. Environmental and genetic contributors to hypospadias. a review of the epidemiologic evidence. Birth Defects Res A Clin Mol Teratol 2012, 94:499-510.
250. Hersmus R., Kalfa N., de Leeuw B., et al. FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD). J Pathol 2008, 215:31-38.
251. Buell-Gutbrod R., Ivanovic M., Montag A., et al. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol 2011, 14:391-395.
252. Deans R., Creighton S.M., Liao L.M., Conway G.S. Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS). patient preferences and clinical evidence. Clin Endocrinol (Oxf) 2012, 76:894-898.
253. Nakhal R.S., Hall-Craggs M., Freeman A., et al. Evaluation of retained testes in adolescent girls and women with complete androgen insensitivity syndrome. Radiology 2013, 268:153-160.
254. Olivier P., Simoneau-Roy J., Francoeur D., et al. Leydig cell tumors in children. contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. J Pediatr 2012, 161:1147-1152.
255. Gourgari E., Saloustros E., Stratakis C.A. Large-cell calcifying Sertoli cell tumors of the testes in pediatrics. Curr Opin Pediatr 2012, 24:518-522.
256. Claahsen-van der Grinten H.L., Sweep F.C., Blickman J.G., et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007, 157:339-344.
257. Ma N.S., Geffner M.E. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008, 20:465-470.
258. Kumanov P., Deepinder F., Robeva R., et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters. a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007, 41:126-131.
259. Deepinder F., Braunstein G.D. Drug-induced gynecomastia. an evidence-based review. Expert Opin Drug Saf 2012, 11:779-795.
260. Demura M., Martin R.M., Shozu M., et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum Mol Genet 2007, 16:2529-2541.
261. Braunstein G.D. Clinical practice. Gynecomastia. N Engl J Med 2007, 357:1229-1237.
262. Mauras N., Bishop K., Merinbaum D., et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 2009, 94:2975-2978.
263. Plourde P.V., Reiter E.O., Jou H.C., et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia. a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:4428-4433.
264. De Luca F., Argente J., Cavallo L., et al. Management of puberty in constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 2001, 14(Suppl. 2):953-957.
265. Lee J.M., Kaciroti N., Appugliese D., et al. Body mass index and timing of pubertal initiation in boys. Arch Pediatr Adolesc Med 2010, 164:139-144.
266. Counts D.R., Pescovitz O.H., Barnes K.M., et al. Dissociation of adrenarche and gonadarche in precocious puberty and in isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1987, 64:1174-1178.
267. Harrington J., Palmert M.R. Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism. critical appraisal of available diagnostic tests. J Clin Endocrinol Metab 2012, 97:3056-3067.
268. Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2012, 97:707-718.
269. Grinspon R.P., Ropelato M.G., Gottlieb S., et al. Basal follicle-stimulating hormone and peak gonadotropin levels after gonadotropin-releasing hormone infusion show high diagnostic accuracy in boys with suspicion of hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2010, 95:2811-2818.
270. Resende E.A., Lara B.H., Reis J.D., et al. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007, 92:1424-1429.
271. Coutant R., Biette-Demeneix E., Bouvattier C., et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. J Clin Endocrinol Metab 2010, 95:5225-5232.
272. Adan L., Lechevalier P., Couto-Silva A.C., et al. Plasma inhibin B and antimullerian hormone concentrations in boys. discriminating between congenital hypogonadotropic hypogonadism and constitutional pubertal delay. Med Sci Monit 2010, 16:CR511-CR517.
273. Harrington J., Palmert M.R. Clinical review. distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadismcritical appraisal of available diagnostic tests. J Clin Endocrinol Metab 2012, 97:3056-3067.
274. Richman R.A., Kirsch L.R. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988, 319:1563-1567.
275. Rosenfeld R.G., Northcraft G.B., Hintz R.L. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics 1982, 69:681-687.
276. Soliman A.T., Khadir M.M., Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. Metabolism 1995, 44:1013-1015.
277. Cohen P., Rogol A.D., Deal C.L., et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature. a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008, 93:4210-4217.
278. Rosenbloom A.L. Idiopathic short stature. conundrums of definition and treatment. Int J Pediatr Endocrinol http://dx.doi:10.1155/2009/470378.
279. Hero M., Norjavaara E., Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature. a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:6396-6402.
280. Wickman S., Sipila I., Ankarberg-Lindgren C., et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty. a randomised controlled trial. Lancet 2001, 357:1743-1748.
281. Hero M., Wickman S., Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clinical Endocrinol 2006, 64:510-513.
282. Mauras N., Gonzalez de Pijem L., Hsiang H.Y., et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone. a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008, 93:823-831.
283. Shulman D.I., Francis G.L., Palmert M.R., Eugster E.A. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008, 121:e975-e983.
284. Wit J.M., Hero M., Nunez S.B. Aromatase inhibitors in pediatrics. Nat Rev Endocrinol 2012, 8:135-147.
285. Warne D.W., Decosterd G., Okada H., et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009, 92:594-604.
286. Pitteloud N., Hayes F.J., Boepple P.A., et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002, 87:152-160.
287. Pitteloud N., Hayes F.J., Dwyer A., et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002, 87:4128-4136.
288. Liu P.Y., Baker H.W., Jayadev V., et al. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men. predictors of fertility outcome. J Clin Endocrinol Metab 2009, 94:801-808.
289. Davies M.J., Moore V.M., Willson K.J., et al. Reproductive technologies and the risk of birth defects. N Engl J Med 2012, 366:1803-1813.
290. Bhasin S., Woodhouse L., Casaburi R., et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001, 281:E1172-E1181.
291. Di Luigi L., Sgrò P., Romanelli F., et al. Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism. concerns on the detection of doping with testosterone in treated hypogonadal athletes. J Endocrinol Invest 2009, 32:445-453.
292. Martínez-Patiño M.J. Personal account. a woman tried and tested. Lancet 2005, 366(Suppl. 1):S38.
293. Wit J.M., Rekers-Mombarg L.T. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab 2002, 87:604-611.
294. Wu F.C., Brown D.C., Butler G.E., et al. Early morning plasma testosterone is an accurate predictor of imminent pubertal development in prepubertal boys. J Clin Endocrinol Metab 1993, 76:26-31.
295. Segal T.Y., Mehta A., Anazodo A., et al. Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J Clin Endocrinol Metab 2009, 94:780-785.
296. Doty R.L., Shaman P., Kimmelman C.P., Dann M.S. University of Pennsylvania Smell Identification Test. a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984, 94:176-178.
297. Wickman S., Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys. evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001, 86:4887-4894.